EXACT SCIENCES CORP's ticker is EXAS and the CUSIP is 30063P105. A total of 616 filers reported holding EXACT SCIENCES CORP in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
About EXACT SCIENCES CORP
Exact Sciences Corp is a leading biotechnology company that specializes in the development of diagnostic tests for the early detection of cancer. The company's flagship product, Cologuard, is a non-invasive screening test for colorectal cancer that has been approved by the FDA.
Exact Sciences Corp has been making significant strides in the field of cancer diagnostics, and its innovative approach has been recognized by the medical community. The company has a strong team of experts, including CEO Kevin Conroy, who has been instrumental in driving the company's growth.
Exact Sciences Corp has also been expanding its product portfolio, with the recent acquisition of Thrive Earlier Detection Corp, a company that is developing a blood test for the early detection of multiple types of cancer. This acquisition is expected to further strengthen the company's position in the cancer diagnostics market.
Despite the challenges posed by the COVID-19 pandemic, Exact Sciences Corp has continued to perform well, with strong revenue growth in the first quarter of 2021. The company's commitment to innovation and its focus on improving cancer detection rates make it a promising investment opportunity for stock market investors.
In conclusion, Exact Sciences Corp is a leading biotechnology company that is making significant strides in the field of cancer diagnostics. With a strong team of experts and a commitment to innovation, the company is well-positioned for future growth and success.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,163 | -27.4% | 105 | 0.0% | 0.00% | – |
| Q2 2023 | $9,860 | +38.5% | 105 | 0.0% | 0.00% | – |
| Q1 2023 | $7,120 | +36.9% | 105 | 0.0% | 0.00% | – |
| Q4 2022 | $5,199 | +73.3% | 105 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | -25.0% | 105 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -42.9% | 105 | 0.0% | 0.00% | – |
| Q1 2022 | $7,000 | -12.5% | 105 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | -20.0% | 105 | -3.7% | 0.00% | – |
| Q3 2021 | $10,000 | -23.1% | 109 | +3.8% | 0.00% | -100.0% |
| Q2 2021 | $13,000 | -7.1% | 105 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $14,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $14,000 | +27.3% | 105 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,000 | +22.2% | 105 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $9,000 | +50.0% | 105 | 0.0% | 0.00% | – |
| Q1 2020 | $6,000 | -40.0% | 105 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $10,000 | +11.1% | 105 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $9,000 | -25.0% | 105 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $12,000 | +33.3% | 105 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $9,000 | +28.6% | 105 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $7,000 | -12.5% | 105 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $8,000 | 0.0% | 105 | -53.3% | 0.00% | 0.0% |
| Q2 2017 | $8,000 | – | 225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 1,556,899 | $143,982,000 | 5.34% |
| Spyglass Capital Management LLC | 387,117 | $35,801,000 | 4.60% |
| R.H. Dinel Investment Counsel, Inc. | 52,900 | $4,892,000 | 4.33% |
| Iron Triangle Partners LP | 139,900 | $12,938,000 | 3.43% |
| ARS Investment Partners, LLC | 214,404 | $19,828,000 | 3.33% |
| Consonance Capital Management LP | 579,666 | $53,608,000 | 3.27% |
| Biondo Investment Advisors, LLC | 153,100 | $14,159,000 | 3.27% |
| Aubrey Capital Management Ltd | 52,750 | $4,878,320,000 | 2.76% |
| RIVERPARK CAPITAL MANAGEMENT LLC | 31,954 | $2,955,000 | 2.60% |
| Voss Capital, LP | 11,000 | $16,443,000 | 2.48% |